IN2014CN02114A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02114A IN2014CN02114A IN2114CHN2014A IN2014CN02114A IN 2014CN02114 A IN2014CN02114 A IN 2014CN02114A IN 2114CHN2014 A IN2114CHN2014 A IN 2114CHN2014A IN 2014CN02114 A IN2014CN02114 A IN 2014CN02114A
- Authority
- IN
- India
- Prior art keywords
- hemagglutinin polypeptides
- glycosylation sites
- same
- flu hemagglutinin
- flu
- Prior art date
Links
- 101710154606 Hemagglutinin Proteins 0.000 abstract 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 3
- 101710176177 Protein A56 Proteins 0.000 abstract 3
- 239000000185 hemagglutinin Substances 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000013595 glycosylation Effects 0.000 abstract 2
- 238000006206 glycosylation reaction Methods 0.000 abstract 2
- 206010022000 influenza Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161536924P | 2011-09-20 | 2011-09-20 | |
| US201161565899P | 2011-12-01 | 2011-12-01 | |
| US201261607526P | 2012-03-06 | 2012-03-06 | |
| US201261648525P | 2012-05-17 | 2012-05-17 | |
| US201261670108P | 2012-07-10 | 2012-07-10 | |
| US201261684481P | 2012-08-17 | 2012-08-17 | |
| PCT/US2012/056122 WO2013043729A1 (en) | 2011-09-20 | 2012-09-19 | Influenza virus vaccines and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02114A true IN2014CN02114A (OSRAM) | 2015-05-29 |
Family
ID=47914828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2114CHN2014 IN2014CN02114A (OSRAM) | 2011-09-20 | 2012-09-19 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10131695B2 (OSRAM) |
| EP (2) | EP2758075B1 (OSRAM) |
| JP (4) | JP6498439B2 (OSRAM) |
| KR (1) | KR20140068205A (OSRAM) |
| CN (3) | CN108164602A (OSRAM) |
| AR (1) | AR090392A1 (OSRAM) |
| AU (2) | AU2012312529B2 (OSRAM) |
| BR (1) | BR112014006694A2 (OSRAM) |
| CA (1) | CA2849434A1 (OSRAM) |
| EA (1) | EA201490659A1 (OSRAM) |
| ES (1) | ES2953393T3 (OSRAM) |
| HK (1) | HK1200102A1 (OSRAM) |
| IL (2) | IL231547B (OSRAM) |
| IN (1) | IN2014CN02114A (OSRAM) |
| MX (1) | MX2014003308A (OSRAM) |
| SG (1) | SG11201400743VA (OSRAM) |
| WO (1) | WO2013043729A1 (OSRAM) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2787099A1 (en) | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
| US8673314B2 (en) | 2009-05-26 | 2014-03-18 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
| US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| WO2011103453A2 (en) | 2010-02-18 | 2011-08-25 | Mount Sinai School Of Medicine | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| CN102939103A (zh) | 2010-03-30 | 2013-02-20 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| US10183069B2 (en) | 2011-03-21 | 2019-01-22 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
| IN2014CN02114A (OSRAM) | 2011-09-20 | 2015-05-29 | Sinai School Medicine | |
| CN108641002A (zh) | 2012-12-18 | 2018-10-12 | 西奈山伊坎医学院 | 流感病毒疫苗及其用途 |
| US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| ES2837392T3 (es) * | 2013-10-02 | 2021-06-30 | Medimmune Llc | Anticuerpos anti-influenza A neutralizantes y usos de los mismos |
| US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
| WO2015164674A1 (en) * | 2014-04-23 | 2015-10-29 | Moderna Therapeutics, Inc. | Nucleic acid vaccines |
| EP3149479A2 (en) * | 2014-05-30 | 2017-04-05 | Sanofi Pasteur Inc. | Expression and conformational analysis of engineered influenza hemagglutinin |
| IL249704B (en) * | 2014-07-10 | 2021-03-25 | Janssen Vaccines & Prevention Bv | Influenza virus vaccines and their uses |
| CA2954780A1 (en) | 2014-07-15 | 2016-01-21 | Medimmune, Llc | Neutralizing anti-influenza b antibodies and uses thereof |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| WO2016118937A1 (en) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| WO2016179099A1 (en) * | 2015-05-04 | 2016-11-10 | Epivax, Inc. | Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3303384B1 (en) | 2015-06-01 | 2021-08-25 | Medimmune, LLC | Neutralizing anti-influenza binding molecules and uses thereof |
| WO2016205347A1 (en) * | 2015-06-16 | 2016-12-22 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
| CN116271017A (zh) | 2016-01-13 | 2023-06-23 | 免疫医疗有限责任公司 | 治疗甲型流感的方法 |
| US10063211B2 (en) | 2016-02-03 | 2018-08-28 | Qualcomm Incorporated | Compact bypass and decoupling structure for millimeter-wave circuits |
| RU2022108149A (ru) * | 2016-02-03 | 2022-05-05 | СиДжи ДИСКАВЕРИ, ИНК. | Композиции гемагглютинина гриппа с гетерологичными эпитопами и/или измененными сайтами расщепления при созревании |
| JP6868763B2 (ja) * | 2016-04-01 | 2021-05-12 | パナソニックＩｐマネジメント株式会社 | インフルエンザウィルスに結合する抗体 |
| IL263416B2 (en) | 2016-06-03 | 2024-10-01 | Sanofi Pasteur Inc | Modification of transgenic influenza hemagglutinin polypeptides |
| US20190125859A1 (en) * | 2016-06-03 | 2019-05-02 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| BR112018075032A2 (pt) | 2016-06-15 | 2019-03-26 | Icahn School Of Medicine At Mount Sinai | proteínas de hemaglutinina do vírus influenza e seus uso |
| KR20240042570A (ko) | 2016-09-02 | 2024-04-02 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도 |
| WO2018085488A1 (en) * | 2016-11-02 | 2018-05-11 | Iowa State University Research Foundation, Inc. | Universal mammalian influenza vaccine |
| US20180128545A1 (en) * | 2016-11-08 | 2018-05-10 | Berry Metal Company | Modular furnace cooling wall |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| WO2018175560A1 (en) * | 2017-03-22 | 2018-09-27 | The Scripps Research Institute | Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain |
| US11254733B2 (en) | 2017-04-07 | 2022-02-22 | Icahn School Of Medicine At Mount Sinai | Anti-influenza B virus neuraminidase antibodies and uses thereof |
| JP7614841B2 (ja) * | 2018-04-03 | 2025-01-16 | サノフイ | 抗原性呼吸器合胞体ウイルスポリペプチド |
| EP3773698A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Ferritin proteins |
| WO2019222674A1 (en) * | 2018-05-18 | 2019-11-21 | Chan Zuckerberg Biohub, Inc. | Epitope restriction for antibody selection |
| WO2019246363A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| US20210225457A1 (en) * | 2018-07-13 | 2021-07-22 | University Of Georgia Research Foundation | Methods for generating pan-epitopic immunogens of influenza h3 virus, compositions and methods of use thereof |
| CN120795059A (zh) | 2018-08-27 | 2025-10-17 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| CN109096376A (zh) * | 2018-09-20 | 2018-12-28 | 扬州大学 | 流感病毒ha多肽、klh偶联多肽及多克隆抗体的制备方法 |
| KR102098585B1 (ko) * | 2018-11-21 | 2020-04-08 | 고려대학교 산학협력단 | 교차 면역원성을 갖는 h2 아형 인플루엔자 바이러스 및 이를 포함하는 백신 |
| JP7621270B2 (ja) | 2019-04-05 | 2025-01-24 | アカデミア シニカ | シアリダーゼ耐性糖およびその調製および使用方法 |
| WO2020210149A1 (en) * | 2019-04-06 | 2020-10-15 | Altimmune Inc | Broad and long-lasting influenza vaccine |
| TWI817041B (zh) * | 2019-09-20 | 2023-10-01 | 中央研究院 | 嵌合血球凝集素蛋白質及包含其之疫苗組成物 |
| CA3158145A1 (en) * | 2019-10-15 | 2021-04-22 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| US12285437B2 (en) | 2019-10-30 | 2025-04-29 | The Research Foundation For The State University Of New York | Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity |
| CA3182526A1 (en) | 2020-05-08 | 2021-11-11 | Academia Sinica | Chimeric influenza vaccines |
| CN112111503B (zh) * | 2020-08-24 | 2023-04-07 | 河北省动物疫病预防控制中心 | 同时预防禽流感h5和h9亚型的腺病毒载体二价苗及其制备方法 |
| WO2022155649A1 (en) * | 2021-01-12 | 2022-07-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Herpes simplex virus type 1 derived influenza vaccine |
| CN113082187B (zh) * | 2021-04-09 | 2023-06-27 | 北京红太阳药业有限公司 | 小柴胡提取物与阿奇霉素联合在治疗病毒性肺炎中的应用 |
| IL318755A (en) | 2021-04-12 | 2025-04-01 | Academia Sinica | Improved vaccine for the coronavirus |
| TW202334429A (zh) | 2021-10-01 | 2023-09-01 | 中央研究院 | Sars-cov-2棘蛋白特異性抗體及其用途 |
| CA3268566A1 (en) | 2023-04-08 | 2024-10-17 | Rock Biomedical Inc | METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES |
| WO2025092866A1 (zh) * | 2023-10-31 | 2025-05-08 | 仁景(苏州)生物科技有限公司 | 一种多价流感mRNA疫苗 |
Family Cites Families (171)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| ZA836080B (en) | 1982-08-23 | 1984-04-25 | Scripps Clinic Res | Broad spectrum influenza antisera |
| US5106619A (en) | 1983-12-20 | 1992-04-21 | Diamond Scientific Co. | Preparation of inactivated viral vaccines |
| US4693981A (en) | 1983-12-20 | 1987-09-15 | Advanced Genetics Research Institute | Preparation of inactivated viral vaccines |
| FR2583429B1 (fr) | 1985-06-18 | 1989-11-03 | Transgene Sa | Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u |
| US5182192A (en) | 1987-03-27 | 1993-01-26 | The Wistar Institute | Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5854037A (en) | 1989-08-28 | 1998-12-29 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
| US5166057A (en) | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
| US6001634A (en) | 1989-08-28 | 1999-12-14 | Palese; Peter | Recombinant negative strand RNA viruses |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6887699B1 (en) | 1990-05-22 | 2005-05-03 | Medimmune Vaccines, Inc. | Recombinant negative strand RNA virus expression systems and vaccines |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| FR2664905B1 (fr) | 1990-07-18 | 1994-08-12 | Agronomique Inst Nat Rech | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5484719A (en) | 1991-08-26 | 1996-01-16 | Edible Vaccines, Inc. | Vaccines produced and administered through edible plants |
| US5612487A (en) | 1991-08-26 | 1997-03-18 | Edible Vaccines, Inc. | Anti-viral vaccines expressed in plants |
| US6034298A (en) | 1991-08-26 | 2000-03-07 | Prodigene, Inc. | Vaccines expressed in plants |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| EP0621339B1 (en) | 1992-09-17 | 2001-10-24 | Takara Shuzo Co. Ltd. | Immunogenic human influenza A virus haemagglutinin polypeptides |
| US6337070B1 (en) | 1993-04-29 | 2002-01-08 | Takara Shuzo Co., Ltd. | Polypeptides for use in generating anti-human influenza virus antibodies |
| US5589174A (en) | 1992-09-17 | 1996-12-31 | Takara Shuzo Co., Ltd. | Anti-human influenza virus antibody |
| JP3037554B2 (ja) | 1993-04-20 | 2000-04-24 | 寳酒造株式会社 | 免疫原性人工ポリペプチド |
| GB9221654D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant human anti-cytomegalovirus antibodies |
| US5674703A (en) | 1992-12-02 | 1997-10-07 | Woo; Savio L. C. | Episomal vector systems and related methods |
| WO1994016109A1 (en) | 1993-01-15 | 1994-07-21 | Whitehead Institute For Biomedical Research | Membrane fusion events and means for altering same |
| WO1994017826A1 (en) | 1993-02-01 | 1994-08-18 | Smithkline Beecham Corporation | Vaccinal polypeptides |
| US5573916A (en) | 1994-05-19 | 1996-11-12 | Coretech, Inc. | Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US5622701A (en) | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
| DK0702085T4 (da) | 1994-07-18 | 2010-04-06 | Conzelmann Karl Klaus Prof Dr | Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus |
| CA2201592A1 (en) | 1994-10-03 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
| KR100654645B1 (ko) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| DE69510207T3 (de) | 1995-08-09 | 2007-02-15 | Schweiz. Serum- & Impfinstitut Bern | Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren |
| US5929304A (en) | 1995-09-14 | 1999-07-27 | Croptech Development Corporation | Production of lysosomal enzymes in plant-based expression systems |
| AU727923B2 (en) | 1995-09-27 | 2001-01-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Production of infectious respiratory syncytial virus from cloned nucleotide sequences |
| JP2820106B2 (ja) | 1996-02-29 | 1998-11-05 | 日本電気株式会社 | トラヒックシェーパ装置 |
| EP0895543B1 (en) | 1996-04-19 | 2006-06-28 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens |
| US6942861B2 (en) | 1996-04-19 | 2005-09-13 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability |
| CA2257823A1 (en) | 1996-07-15 | 1998-01-22 | Government Of The United States Of America As Represented By The Secreta Ry Of The Department Of Health And Human Services National Institutes Of | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
| IL155588A0 (en) | 2003-04-27 | 2003-11-23 | Metabogal Ltd | Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby |
| US20050032211A1 (en) | 1996-09-26 | 2005-02-10 | Metabogal Ltd. | Cell/tissue culturing device, system and method |
| BR9712138A (pt) | 1996-09-27 | 2000-01-18 | American Cyanamid Co | Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição. |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| PT1500329E (pt) | 1996-12-03 | 2012-06-18 | Amgen Fremont Inc | Anticorpos humanos que se ligam especificamente ao tnf alfa humano |
| US5891705A (en) | 1997-04-08 | 1999-04-06 | Pentose Pharmaceuticals, Inc. | Method for inactivating a virus |
| RU2224766C2 (ru) | 1997-04-14 | 2004-02-27 | Микромет Аг | Способ получения рецепторов для человеческих антигенов и их применение |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CA2291216A1 (en) | 1997-05-23 | 1998-11-26 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences |
| US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| EP1012244B1 (en) | 1997-07-11 | 2007-05-09 | Yale University | Rhabdoviruses with reengineered coats |
| BR9812232A (pt) | 1997-09-19 | 2000-07-18 | American Cyanamid Co | Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico |
| AU748416B2 (en) | 1998-06-12 | 2002-06-06 | Andrej Egorov | Interferon inducing genetically engineered attenuated viruses |
| PL219128B1 (pl) | 1998-06-12 | 2015-03-31 | Sinai School Medicine | Genetycznie zmodyfikowane atenuowane chimerowe wirusy grypy, preparat szczepionki, kompozycja farmaceutyczna, kompozycja farmaceutyczna do zastosowania oraz zastosowania takich wirusów |
| US6146642A (en) | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
| US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
| US6551820B1 (en) | 1998-12-23 | 2003-04-22 | Boyce Thompson Institute For Plant Research | Expression of immunogenic hepatitis B surface antigens in transgenic plants |
| AT407958B (de) | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
| MXPA01010921A (es) | 1999-04-29 | 2003-06-24 | Syngenta Ltd | Plantas resistentes a herbicidas. |
| DE122007000070I1 (de) | 1999-07-14 | 2008-01-31 | Sinai School Medicine | In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren |
| WO2001021151A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Intranasal influenza virus vaccine |
| US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| AU2001250856A1 (en) | 2000-03-17 | 2001-10-03 | Charles Arntzen | Expression of recombinant human acetylcholinesterase in transgenic plants |
| HU229101B1 (en) | 2000-04-28 | 2013-07-29 | St Jude Childrens Res Hospital | Dna transfection system for the generation of infectious influenza virus |
| US6632620B1 (en) | 2000-06-22 | 2003-10-14 | Andrew N. Makarovskiy | Compositions for identification and isolation of stem cells |
| WO2002000885A2 (en) * | 2000-06-23 | 2002-01-03 | American Cyanamid Company | Assembly of wild-type and chimeric influenza virus-like particles (vlps) |
| ES2806412T3 (es) | 2002-02-13 | 2021-02-17 | Wisconsin Alumni Res Found | Señal para el empaquetamiento de vectores del virus de la gripe |
| US20040091503A1 (en) | 2002-08-20 | 2004-05-13 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
| JP4892705B2 (ja) * | 2002-08-20 | 2012-03-07 | オプサニテクス エルエルシー | レクチン組成物および抗原に対する免疫反応を調節するための方法 |
| US20070036809A1 (en) | 2003-01-29 | 2007-02-15 | Josef Michl | Tolerance-induced targeted antibody production |
| JP4675317B2 (ja) | 2003-01-30 | 2011-04-20 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | アジュバント化インフルエンザワクチン |
| US7695725B2 (en) | 2003-02-06 | 2010-04-13 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
| JP4368594B2 (ja) | 2003-02-24 | 2009-11-18 | 株式会社インシリコサイエンス | タンパク質構造予測装置、タンパク質構造予測方法、プログラム、および、記録媒体 |
| US7951557B2 (en) | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| BRPI0410340A (pt) | 2003-05-05 | 2006-05-30 | Dow Agrosciences Llc | vetores e células para preparar composições imunoprotetoras derivadas de plantas transgênicas |
| CA2816222A1 (en) | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| US8551756B2 (en) | 2003-07-11 | 2013-10-08 | Novavax, Inc. | Avian influenza chimeric VLPS |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| DK2261375T3 (da) | 2003-11-04 | 2013-04-22 | Univ Tulane | Fremgangsmåde til hindring af viruscellefusion ved hæmning af funktionen af fusionsinitieringsområdet i RNA-vira med klasse I membranfusogene kappeproteiner |
| US7504109B2 (en) | 2004-05-25 | 2009-03-17 | Medimmune, Llc | Influenza hemagglutinin and neuraminidase variants |
| ATE468390T1 (de) | 2004-10-13 | 2010-06-15 | Protalix Ltd | System und verfahren zur produktion von antikörpern in der pflanzenzellkultur |
| CA2586690A1 (en) * | 2004-11-03 | 2006-06-15 | Novartis Vaccines And Diagnostics, Inc. | Influenza vaccination |
| CA2598884A1 (en) | 2005-02-24 | 2006-10-05 | University Of Massachusetts | Influenza nucleic acids, polypeptides, and uses thereof |
| EP1885186B1 (en) | 2005-06-01 | 2015-09-02 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| JP4758148B2 (ja) | 2005-06-14 | 2011-08-24 | 泰三 宇田 | インフルエンザウイルスのヘマグルチニンに対する抗体酵素 |
| KR20070000554A (ko) | 2005-06-27 | 2007-01-03 | 삼성전자주식회사 | 이종 망에서 복합 서비스를 위한 자원 관리방법 |
| PE20070171A1 (es) | 2005-06-30 | 2007-03-08 | Boehringer Ingelheim Int | GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa |
| US7951384B2 (en) | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| JP2009514841A (ja) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 粒子状アジュバントと免疫増強物質との組合せを含むインフルエンザワクチン |
| HUE037464T2 (hu) | 2005-12-02 | 2018-08-28 | Icahn School Med Mount Sinai | Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk |
| DK1968632T3 (da) | 2005-12-06 | 2012-07-16 | Yeda Res & Dev | Forbedret influenzavaccine |
| US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
| AU2007215080A1 (en) | 2006-02-13 | 2007-08-23 | Fraunhofer Usa, Inc. | Influenza antigens, vaccine compositions, and related methods |
| US20070207171A1 (en) | 2006-03-01 | 2007-09-06 | Cerus Corporation | Engineered listeria and methods of use thereof |
| AU2007224034B2 (en) | 2006-03-07 | 2012-03-29 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| WO2007109812A2 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| CA2646349A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
| WO2007130330A2 (en) | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Polyvalent influenza virus-like particle (vlp) compositions |
| US20070262178A1 (en) | 2006-05-12 | 2007-11-15 | Ultradent Products, Inc. | Syringe delivery tip including an enlarged flocked wing element adjacent a distal delivery end |
| US8148085B2 (en) | 2006-05-15 | 2012-04-03 | Sea Lane Biotechnologies, Llc | Donor specific antibody libraries |
| CA2652452C (en) | 2006-05-15 | 2018-07-31 | Sea Lane Biotechnologies, Llc | Neutralizing antibodies to influenza viruses |
| CA2657849A1 (en) | 2006-05-18 | 2008-05-08 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| WO2008002238A1 (en) | 2006-06-27 | 2008-01-03 | Addbio Ab | Drug delivery device , kit and method for peroperative local pharmacological treatment of bone surfaces |
| EP2035565A4 (en) | 2006-06-30 | 2010-07-21 | Novavax Inc | METHODS OF ENHANCING THE INCORPORATION OF PROTEINS IN VIRUS-LIKE PARTICLES (VLPs) |
| CA2659529C (en) | 2006-07-21 | 2016-11-01 | California Institute Of Technology | Targeted gene delivery for dendritic cell vaccination |
| EP2450377A1 (en) | 2006-09-07 | 2012-05-09 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof |
| ES2694805T7 (es) | 2006-09-11 | 2021-10-21 | Seqirus Uk Ltd | Fabricación de vacunas contra virus de la gripe sin usar huevos |
| ES2609818T3 (es) | 2007-06-15 | 2017-04-24 | Xiamen University | Anticuerpos monoclonales que se unen a hemaglutinina del virus de la gripe aviar del subtipo H5 y usos de los mismos |
| EP2014279A1 (en) | 2007-06-22 | 2009-01-14 | Pevion Biotech AG | Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof |
| CN101784283A (zh) | 2007-06-27 | 2010-07-21 | 诺华有限公司 | 低添加流感疫苗 |
| CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
| HUE025702T2 (en) | 2007-07-19 | 2016-04-28 | Novavax Inc | Avian Flu Chimeric VLPs |
| US20090092635A1 (en) | 2007-08-17 | 2009-04-09 | Wyeth | Heterologous prime-boost immunization regimen |
| WO2009088401A2 (en) | 2007-09-24 | 2009-07-16 | Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Immunostimulatory combinations of tlr ligands and methods of use |
| FR2921387B1 (fr) | 2007-09-26 | 2012-04-20 | Sanofi Pasteur | Procede de production du virus de la grippe |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| CA2707235C (en) | 2007-11-27 | 2013-11-19 | Medicago Inc. | Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin |
| NZ586611A (en) * | 2007-12-06 | 2012-09-28 | Dana Farber Cancer Inst Inc | Antibodies against influenza virus and methods of use thereof |
| WO2009092038A1 (en) | 2008-01-16 | 2009-07-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Influenza dna vaccination and methods of use thereof |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| US20100040635A1 (en) | 2008-03-28 | 2010-02-18 | Sea Lane Biotechnologies | Neutralizing antibodies to influenza viruses |
| GB0905570D0 (en) | 2009-03-31 | 2009-05-13 | Novartis Ag | Combined vaccines |
| EP2540740B1 (en) | 2008-06-17 | 2014-09-10 | Apogenix GmbH | Multimeric TNF receptors |
| JP5756750B2 (ja) | 2008-06-25 | 2015-07-29 | インセルム（インスティチュート ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） | フラジェリンに基づく新規の免疫アジュバント化合物及びその使用 |
| US8771703B2 (en) * | 2008-07-08 | 2014-07-08 | Medicago Inc. | Soluble recombinant influenza antigens |
| WO2010036948A2 (en) | 2008-09-26 | 2010-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Dna prime/inactivated vaccine boost immunization to influenza virus |
| CA2787099A1 (en) | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
| WO2010130636A1 (en) | 2009-05-11 | 2010-11-18 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
| US8673314B2 (en) | 2009-05-26 | 2014-03-18 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| CA2762042C (en) | 2009-06-24 | 2012-11-20 | Medicago Inc. | Chimeric influenza virus-like particles comprising hemagglutinin |
| WO2011014645A1 (en) | 2009-07-30 | 2011-02-03 | Mount Sinai School Of Medicine Of New York University | Influenza viruses and uses thereof |
| JP5463107B2 (ja) * | 2009-09-14 | 2014-04-09 | 独立行政法人国立国際医療研究センター | 新型インフルエンザを特異的に鑑別するモノクローナル抗体とそれを利用した免疫検出試薬 |
| WO2011044152A1 (en) | 2009-10-05 | 2011-04-14 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer | Protection against pandemic and seasonal strains of influenza |
| JP2013060367A (ja) | 2010-01-15 | 2013-04-04 | Osaka Univ | 抗インフルエンザ抗体及びインフルエンザ検出用デバイス |
| US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| WO2011103453A2 (en) | 2010-02-18 | 2011-08-25 | Mount Sinai School Of Medicine | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| EA201400855A1 (ru) | 2010-03-08 | 2014-11-28 | Селлтрион, Инк. | Моноклональные антитела человека, полученные из в-клеток человека и обладающие нейтрализующей активностью против вирусов гриппа а |
| CN102939103A (zh) | 2010-03-30 | 2013-02-20 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| WO2012009790A1 (en) | 2010-07-22 | 2012-01-26 | Schrader John W | Cross-protective pathogen protection, methods and compositions thereof |
| IN2014CN02114A (OSRAM) | 2011-09-20 | 2015-05-29 | Sinai School Medicine | |
| JP6294828B2 (ja) | 2011-11-28 | 2018-03-14 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | インフルエンザウイルスワクチンおよびその使用 |
| CA2894506C (en) | 2012-12-11 | 2021-08-10 | Vib Vzw | Anti-influenza antibody |
| CN108641002A (zh) | 2012-12-18 | 2018-10-12 | 西奈山伊坎医学院 | 流感病毒疫苗及其用途 |
| MX2015008847A (es) | 2013-01-10 | 2015-10-30 | Novartis Ag | Composiciones inmunogenicas de virus de influenza y usos de las mismas. |
| WO2014141125A2 (en) | 2013-03-13 | 2014-09-18 | Novartis Ag | Influenza virus reassortment |
| US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| IL241552B2 (en) | 2013-03-14 | 2023-09-01 | Contrafect Corp | Preparation and methods based on neutralizing antibodies administered intranasally for increased therapeutic efficacy |
| CN105007938A (zh) | 2013-03-15 | 2015-10-28 | 宾夕法尼亚大学理事会 | 流感核酸分子和由其制备的疫苗 |
| PL235555B1 (pl) | 2014-06-24 | 2020-09-07 | Inst Biotechnologii I Antybiotykow | Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu |
| WO2016118937A1 (en) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| WO2016205347A1 (en) | 2015-06-16 | 2016-12-22 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
| US20190125859A1 (en) | 2016-06-03 | 2019-05-02 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| BR112018075032A2 (pt) | 2016-06-15 | 2019-03-26 | Icahn School Of Medicine At Mount Sinai | proteínas de hemaglutinina do vírus influenza e seus uso |
-
2012
- 2012-09-19 IN IN2114CHN2014 patent/IN2014CN02114A/en unknown
- 2012-09-19 SG SG11201400743VA patent/SG11201400743VA/en unknown
- 2012-09-19 EA EA201490659A patent/EA201490659A1/ru unknown
- 2012-09-19 BR BR112014006694-9A patent/BR112014006694A2/pt not_active Application Discontinuation
- 2012-09-19 WO PCT/US2012/056122 patent/WO2013043729A1/en not_active Ceased
- 2012-09-19 EP EP12833955.3A patent/EP2758075B1/en active Active
- 2012-09-19 ES ES12833955T patent/ES2953393T3/es active Active
- 2012-09-19 EP EP23170060.0A patent/EP4241785A3/en active Pending
- 2012-09-19 HK HK15100549.9A patent/HK1200102A1/xx unknown
- 2012-09-19 AU AU2012312529A patent/AU2012312529B2/en not_active Ceased
- 2012-09-19 MX MX2014003308A patent/MX2014003308A/es unknown
- 2012-09-19 CA CA2849434A patent/CA2849434A1/en active Pending
- 2012-09-19 JP JP2014531931A patent/JP6498439B2/ja not_active Expired - Fee Related
- 2012-09-19 KR KR1020147010261A patent/KR20140068205A/ko not_active Ceased
- 2012-09-19 CN CN201710930398.2A patent/CN108164602A/zh active Pending
- 2012-09-19 CN CN201280057023.5A patent/CN104185476A/zh active Pending
- 2012-09-19 CN CN202310147642.3A patent/CN116162175A/zh active Pending
- 2012-09-19 US US14/345,816 patent/US10131695B2/en active Active
- 2012-09-20 AR ARP120103481A patent/AR090392A1/es unknown
-
2014
- 2014-03-16 IL IL231547A patent/IL231547B/en active IP Right Grant
-
2018
- 2018-02-14 JP JP2018024070A patent/JP2018110585A/ja active Pending
- 2018-04-04 AU AU2018202388A patent/AU2018202388A1/en not_active Abandoned
- 2018-09-24 US US16/139,502 patent/US20190106461A1/en not_active Abandoned
- 2018-10-04 IL IL262123A patent/IL262123A/en unknown
-
2020
- 2020-01-29 JP JP2020012913A patent/JP2020096604A/ja active Pending
-
2022
- 2022-03-07 JP JP2022034315A patent/JP2022091775A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014006694A2 (pt) | 2020-11-17 |
| JP2020096604A (ja) | 2020-06-25 |
| CN104185476A (zh) | 2014-12-03 |
| EP2758075B1 (en) | 2023-05-03 |
| AU2018202388A1 (en) | 2018-04-26 |
| US20190106461A1 (en) | 2019-04-11 |
| US20150132330A1 (en) | 2015-05-14 |
| CA2849434A1 (en) | 2013-03-28 |
| IL262123A (en) | 2018-11-29 |
| MX2014003308A (es) | 2015-03-09 |
| IL231547A0 (en) | 2014-04-30 |
| EP4241785A2 (en) | 2023-09-13 |
| AR090392A1 (es) | 2014-11-12 |
| AU2012312529B2 (en) | 2018-01-04 |
| JP2022091775A (ja) | 2022-06-21 |
| JP2014530003A (ja) | 2014-11-17 |
| AU2012312529A1 (en) | 2014-03-27 |
| SG11201400743VA (en) | 2014-04-28 |
| CN108164602A (zh) | 2018-06-15 |
| EP4241785A3 (en) | 2023-09-27 |
| EP2758075A4 (en) | 2015-05-20 |
| KR20140068205A (ko) | 2014-06-05 |
| US10131695B2 (en) | 2018-11-20 |
| EA201490659A1 (ru) | 2014-11-28 |
| CN116162175A (zh) | 2023-05-26 |
| JP6498439B2 (ja) | 2019-04-17 |
| HK1200102A1 (en) | 2015-07-31 |
| JP2018110585A (ja) | 2018-07-19 |
| IL231547B (en) | 2018-10-31 |
| EP2758075A1 (en) | 2014-07-30 |
| WO2013043729A1 (en) | 2013-03-28 |
| ES2953393T3 (es) | 2023-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN02114A (OSRAM) | ||
| MX2021001053A (es) | Vacunas contra virus de la influenza y sus usos. | |
| ZA201404797B (en) | Influenza virus vaccines and uses thereof | |
| EP2552479A4 (en) | INFLUENZA VIRUS VACCINES AND USES THEREOF | |
| ZA201200481B (en) | Chimeric influenza virus-like particles comprising hemagglutinin | |
| MX2012009581A (es) | Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza. | |
| GB201115214D0 (en) | Influenza virus antibody compositions | |
| ZA201509229B (en) | Influenza virus vaccines and uses thereof | |
| IL240936B (en) | Reassortment of influenza virus and methods for their preparation | |
| SG10201913435TA (en) | Compositions and methods for dengue virus chimeric constructs in vaccines | |
| EA201590860A1 (ru) | Варианты гемагглютинина и нейраминидазы вируса свиного гриппа | |
| IL227947A0 (en) | Preparations containing antibodies that bind to the glycoprotein hemagglutinin a and the extracellular domain of the polypeptide to the transverse domain of matrix 2 (e2m) from influenza virus origin and their uses | |
| PL2969005T3 (pl) | Atenuowane wirusy grypy i szczepionki | |
| EP3212672A4 (en) | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development | |
| EP3013852A4 (en) | Methods and compositions for dengue virus vaccines | |
| EP2632941A4 (en) | RECOMBINANT HEMAGGLUTININE PROTEIN OF THE INFLUENZA VIRUS AND VACCINE THEREWITH | |
| BR112014002290A2 (pt) | vírus recombinante de influenza suína e usos do mesmo | |
| HK40089224A (en) | Compositions and methods for dengue virus chimeric constructs in vaccines | |
| HK1180225A (en) | Influenza virus vaccines and uses thereof | |
| HK1192850A (en) | Inactivated dengue virus vaccine |